Hagen B, Walstad R A, Nilsen O G
Department of Pharmacology and Toxicology, University of Trondheim, Norway.
Cancer Chemother Pharmacol. 1988;22(4):356-8. doi: 10.1007/BF00254246.
Thio-TEPA pharmacokinetics were studied at doses of 20 mg and 30 mg in six patients treated for ovarian cancer. Considerable interindividual variation was encountered in its pharmacokinetics, which were dose-independent within the dose range studied and similar to those reported at far higher doses. Interindividual dosing of thio-TEPA based on an initial AUC estimation is suggested.
在六名接受卵巢癌治疗的患者中,研究了硫替派在20毫克和30毫克剂量下的药代动力学。其药代动力学存在相当大的个体间差异,在所研究的剂量范围内与剂量无关,且与在高得多的剂量下报告的情况相似。建议根据初始AUC估计进行硫替派的个体化给药。